Kailera Therapeutics Inc. , a clinical-stage biotechnology company focused on obesity, raised $625 million in an upsized initial public offering, marking the sector’s biggest US listing since 2021. The Waltham, Massachusetts-based company’s IPO priced at the top of its marketed range. Kailera sold about 39 million shares at $16 each, according to a statement Thursday. The biotech had offered 33.3 ...
Kailera Therapeutics Inc. , a clinical-stage biotechnology company focused on obesity, raised $625 million in an upsized initial public offering, marking the sector’s biggest US listing since 2021. The Waltham, Massachusetts-based company’s IPO priced at the top of its marketed range. Kailera sold about 39 million shares at $16 each, according to a statement Thursday. The biotech had offered 33.3 million shares for $14 to $16 each. The IPO was double-digits oversubscribed, people familiar with the matter have said . At the IPO price, Kailera has a market value of about $2 billion based on the outstanding shares listed in the filing. The listing is the biggest US biotech debut since 2021, when cell-engineering firm Sana Biotechnology Inc. raised $676 million, according to data compiled by Bloomberg. Kailera will join a crowded field of drugmakers jockeying to win a slice of what could be a $200 billion obesity market by 2030. Eli Lilly & Co and Novo Nordisk A/S lead the pack with US FDA approved weight loss pills and shots already available to patients. Founded in 2024, the late clinical-stage biotech is developing four GLP-1 based weight loss drugs, including a weekly shot and once-daily oral tablet which are in late stage trials. Existing shareholders including Bain Capital Private Equity , Bain Capital Life Sciences and Qatar Investment Authority have indicated an interest in buying as much as $225 million of shares in aggregate at the IPO price. Affiliates of Bain Capital will own about a third of the company after the offering, according to the filing. Kailera reported a net loss of $149 million for the year ended December 2025, compared with a net loss of $219.7 million from its inception in May 2024 to December 2024. Kailera is led by Ronald Renaud , the chief executive officer of Cerevel Therapeutics until the close of its $8.7 billion acquisition by AbbVie Inc. in 2024. For the latest news on equity capital markets activity in the US, Canada and Latin Americ...
SlavkoSereda/iStock via Getty Images Crude oil futures gained Thursday after the U.S. said it was expanding its blockade of Iran to "all ships, regardless of nationality" and will pursue Iran-linked ships beyond the Middle East if necessary, while continuing the blockade as long as necessary. But President Trump announced that the leaders of Israel and Lebanon reached a 10-day ceasefire deal after...
SlavkoSereda/iStock via Getty Images Crude oil futures gained Thursday after the U.S. said it was expanding its blockade of Iran to "all ships, regardless of nationality" and will pursue Iran-linked ships beyond the Middle East if necessary, while continuing the blockade as long as necessary. But President Trump announced that the leaders of Israel and Lebanon reached a 10-day ceasefire deal after weeks of fighting between Israel and Iran-backed Hezbollah and said prospects for a deal with Iran are "looking very good," with the two sides in discussions to extend a ceasefire ahead of its expiration next week. " The market is balancing improving headlines with the reality that every delay in normalization means further supply loss and tighter near-term fundamentals," CIBC Private Wealth Group senior energy trader Rebecca Babin said in a note. "While there's been some positive geopolitical progress, it hasn't translated into real movement on flows, which remain clearly constrained." Given the damage to energy infrastructure in the Middle East, International Energy Agency head Fatih Birol warned that Europe has "maybe six weeks or so" of jet fuel remaining, and it could take up to two years to recover a significant share of oil and gas production that has been disrupted. Analysts from ING estimate that ~13M bbl/day of oil flow has been disrupted by the closure of the Strait of Hormuz. Front-month Nymex crude ( CL1:COM ) for May delivery jumped 3.7% to $94.69/bbl, and front-month Brent crude ( CO1:COM ) for June delivery climbed 4.7% to $99.39/bbl. U.S. natural gas futures ( NG1:COM ) rose modestly as the market paid little attention to an above-average 59 Bcf storage build that increased the inventory surplus over the five-year average; the front-month Nymex May contract closed up 1.4% at $2.647/MMBtu. ETFs: ( USO ), ( BNO ), ( UCO ), ( SCO ), ( USL ), ( DBO ), ( DRIP ), ( GUSH ), ( USOI ), ( UNG ), ( BOIL ), ( KOLD ), ( UNL ), ( FCG ), ( XLE ) More on crude oil New H...
China has crafted markets, mechanisms and incentives as the world’s largest buyer of commodities in a bid to free itself from its dependence on the US dollar, but the biggest threat to Washington’s global dollar dominance may well be Washington itself, witnesses said in testimony on Thursday before a key advisory committee to the US Congress. Economic sanctions and access to US-led global banking ...
China has crafted markets, mechanisms and incentives as the world’s largest buyer of commodities in a bid to free itself from its dependence on the US dollar, but the biggest threat to Washington’s global dollar dominance may well be Washington itself, witnesses said in testimony on Thursday before a key advisory committee to the US Congress. Economic sanctions and access to US-led global banking systems are a powerful US tool that can be used to great effect, said experts before the US-China...